14490-19-8

Basic information

• Product Name: 1,4-DICHLOROPYRIDO[4,3-D]PYRIDAZINE
• Synonyms: 1,4-DICHLOROPYRIDO[4,3-D]PYRIDAZINE;3-d]pyridazine;4-dichloropyrido[4;1,4-dichloropyrido[3,4-d]pyridazine;Pyrido[3,4-d]pyridazine, 1,4-dichloro-
• CAS NO: 14490-19-8
• Molecular Formula: C₇H₃Cl₂N₃
• Molecular Weight: 200.02
• EINECS: 200-001-2
• Product Categories: CHIRAL CHEMICALS
• Mol File: 14490-19-8.mol

Chemical Properties

• Melting Point: 159 °C
• Boiling Point: 440.774 °C at 760 mmHg
• Flash Point: 252.94 °C
• Appearance: /
• Density: 1.573 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.682
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.19±0.30(Predicted)
• CAS DataBase Reference: 1,4-DICHLOROPYRIDO[4,3-D]PYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DICHLOROPYRIDO[4,3-D]PYRIDAZINE(14490-19-8)
• EPA Substance Registry System: 1,4-DICHLOROPYRIDO[4,3-D]PYRIDAZINE(14490-19-8)

Safety Data

• Hazardous Substances Data: 14490-19-8(Hazardous Substances Data)

Usage

Uses

1,4-Dichloropyrido[4,3-d]pyridazine is a useful research chemical.

InChI:InChI=1/C7H3Cl2N3/c8-6-4-1-2-10-3-5(4)7(9)12-11-6/h1-3H

Upstream product

• 31384-08-4 2,3-dihydropyrido[3,4-d]pyridazine-1,4-dione 
• 490-11-9 3,4-pyridinecarboxylic acid 
• 4664-08-8 cinchomeronic anhydride 
• 31384-08-4 pyrido[3,4-d]pyridazine-1,4-diol 

Downstream Products

• 87544-92-1 1-(2-acetoxyethylamino)pyrido<3,4-d>pyridazine-4(3H)-one 
• 1353967-68-6 1-[2-(2-fluoro-phenyl)-[1,8]naphthyridin-4-yl]-4-methoxy-pyrido[3,4-d]pyridazine 
• 1365802-59-0 methyl 4-(4-{[3-(trifluoromethyl)phenyl]amino}pyrido[3,4-d]pyridazin-1-yl)benzoate 
• 1365803-35-5 1-chloro-N-(3-(trifluoromethyl)phenyl)pyrido[4,3-d]pyridazin-4-amine 

Relevant articles and documents

Pyrido/pyridazocyclic compound and application thereof

The invention discloses a pyrido/pyridazocyclic compound, a pharmaceutically acceptable salt and a solvent compound thereof. The invention further provides a preparation method of the compound, a composition with the compound and application of the compound for preparing medicines for treating diseases or disorders related to EED (embryonic ectoderm development) protein and/or PRC2 (polycomb repressive complex 2) protein composition action mechanisms.

PYRIDAZINE DERIVATIVES AS HEDGEHOG PATHWAY INHIBITORS

This invention relates to novel compounds. The compounds of the invention are hedgehog pathway agonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) agonists. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS

This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines

Pyridopyridazine antagonists of the hedgehog signaling pathway are described. Designed to optimize our previously described phthalazine smoothened antagonists, a representative compound eliminates a PXR liability while retaining potency and in vitro metab

ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING

The present invention relates generally to compounds represented in Formula (I), pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.